UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10−Q

(Mark One)

 

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: June 30, 2014

 

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ____________ to _____________

 

Commission File Number: 001-34566

 

CHINA BIOLOGIC PRODUCTS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware	75-2308816
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

 

18th Floor, Jialong International Building

19 Chaoyang Park Road

Chaoyang District, Beijing 100125

People’s Republic of China

(Address of principal executive offices, Zip Code)

 

(+86) 10-6598-3111

(Registrant’s telephone number, including area code)

 

_____________________________________________________

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

		Large accelerated filer ¨		Accelerated filer x
		Non-accelerated filer ¨ (Do not check if a smaller reporting company)		Smaller reporting company ¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ¨ No x

 

The number of shares outstanding of each of the issuer’s classes of common stock, as of August 5, 2014 is as follows:

 

	Class of Securities		Shares Outstanding
	Common Stock, $0.0001 par value		24,481,096

 

 

 

Quarterly Report on Form 10-Q

Three and Six Months Ended June 30, 2014

 

TABLE OF CONTENTS

 

PART I

FINANCIAL INFORMATION

 

Item 1.     Financial Statements	1
Item 2.     Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3.     Quantitative and Qualitative Disclosures About Market Risk	24
Item 4.     Controls and Procedures	25

 

PART II

OTHER INFORMATION

 

Item 1.     Legal Proceedings	26
Item 1A.  Risk Factors	27
Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds	27
Item 3.     Defaults Upon Senior Securities	27
Item 4.     Mine Safety Disclosures	27
Item 5.     Other Information	27
Item 6.     Exhibits	28

 

 

PART I

FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES

INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

Contents	Page
Unaudited Condensed Consolidated Balance Sheets	1
Unaudited Condensed Consolidated Statements of Comprehensive Income	2
Unaudited Condensed Consolidated Statements of Changes in Equity	3
Unaudited Condensed Consolidated Statements of Cash Flows	4
Notes to the Unaudited Condensed Consolidated Financial Statements	6

 

 

CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

 

 

		Note				June 30, 2014				December 31, 2013
						USD				USD
ASSETS
Current Assets
Cash and cash equivalents							103,223,625				144,138,487
Time deposit							-				6,608,612
Restricted deposits			6				30,387,500				-
Accounts receivable, net of allowance for doubtful accounts			2				24,598,123				17,270,132
Inventories			3				94,812,741				88,634,855
Prepayments and other current assets							8,962,789				7,641,061
Total Current Assets							261,984,778				264,293,147
Property, plant and equipment, net			4				76,966,843				73,149,072
Land use rights, net							9,407,386				8,213,145
Deposits related to land use rights			5				11,941,943				13,667,130
Restricted cash and deposits, excluding current portion			6				71,753,816				30,523,674
Equity method investment							13,127,429				11,349,807
Other non-current assets							4,271,138				2,585,232
Total Assets							449,453,333				403,781,207
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Short-term bank loans, including current portion of long-term bank loans			7				34,875,000				9,822,000
Accounts payable							3,975,739				4,445,732
Due to related parties			13				6,845,003				7,206,970
Other payables and accrued expenses							31,224,373				34,852,740
Advance from customers							4,577,531				2,908,853
Income tax payable							4,536,159				4,202,405
Total Current Liabilities							86,033,805				63,438,700
Long-term bank loans, excluding current portion			7				70,000,000				30,000,000
Deferred income							2,907,328				3,003,895
Other liabilities							4,041,464				3,369,003
Total Liabilities							162,982,597				99,811,598
Stockholders’ Equity
Common stock:
par value $0.0001;
100,000,000 shares authorized;
27,540,800 and 27,341,744 shares issued at June 30, 2014 and December 31, 2013, respectively;
23,561,096 and 25,862,040 shares outstanding at June 30, 2014 and December 31, 2013, respectively							2,754				2,734
Additional paid-in capital							76,267,027				72,031,864
Treasury stock: 3,979,704 and 1,479,704 shares at June 30, 2014 and December 31, 2013, respectively, at cost			15				(99,594,080	)			(29,594,080	)
Retained earnings							211,743,177				173,744,551
Accumulated other comprehensive income							19,396,652				21,506,494
Total equity attributable to China Biologic Products, Inc.							207,815,530				237,691,563
Noncontrolling interest							78,655,206				66,278,046
Total Stockholders’ Equity							286,470,736				303,969,609
Commitments and contingencies			12				-				-
Total Liabilities and Stockholders’ Equity							449,453,333				403,781,207

 

 

See accompanying notes to Unaudited Condensed Consolidated Financial Statements.

 

 

CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

 

 

						For the three months ended								For the six months ended
		Note				June 30, 2014				June 30, 2013				June 30, 2014				June 30, 2013
						USD				USD				USD				USD
Sales			11				60,073,984				53,580,523				116,340,561				107,612,255
Cost of sales							18,919,981				16,122,262				36,635,147				32,739,020
Gross profit							41,154,003				37,458,261				79,705,414				74,873,235
Operating expenses
Selling expenses							3,329,175				2,441,727				5,611,661				4,278,120
General and administrative expenses							7,112,798				8,866,071				14,329,424				17,553,168
Research and development expenses							1,838,795				835,150				2,912,361				1,748,242
Income from operations							28,873,235				25,315,313				56,851,968				51,293,705
Other income (expenses)
Equity in income of an equity method investee							1,523,216				610,997				1,860,579				739,945
Interest expense							(862,957	)			(198,739	)			(1,484,164	)			(434,913	)
Interest income							1,724,324				995,757				3,320,202				1,643,819
Total other income, net							2,384,583				1,408,015				3,696,617				1,948,851
Earnings before income tax expense							31,257,818				26,723,328				60,548,585				53,242,556
Income tax expense			8				4,486,157				3,745,649				9,824,375				8,352,551
Net income							26,771,661				22,977,679				50,724,210				44,890,005
Less: Net income attributable to noncontrolling interest							7,046,706				6,815,753				12,725,584				13,812,219
Net income attributable to China Biologic Products, Inc.							19,724,955				16,161,926				37,998,626				31,077,786
Net income per share of common stock:			14
Basic							0.83				0.60				1.55				1.15
Diluted							0.79				0.57				1.47				1.11
Weighted average shares used in computation:			14
Basic							23,483,090				26,880,459				24,212,766				26,833,262
Diluted							24,719,011				28,067,303				25,435,122				27,967,080
Net income							26,771,661				22,977,679				50,724,210				44,890,005
Other comprehensive income:
Foreign currency translation adjustment, net of nil income taxes							527,203				4,428,715				(2,589,440	)			5,825,256
Comprehensive income							27,298,864				27,406,394				48,134,770				50,715,261
Less: Comprehensive income attributable to noncontrolling interest							7,140,585				7,723,790				12,245,986				14,882,947
Comprehensive income attributable to China Biologic Products, Inc.							20,158,279				19,682,604				35,888,784				35,832,314

 

 

 

  

See accompanying notes to Unaudited Condensed Consolidated Financial Statements.

 

 

CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

 

FOR THE SIX MONTHS ENDED JUNE 30, 2014

 

																						Accumulated				Equity
		Common stock								Additional												other				attributable
		Number of								paid-in				Retained				Treasury				comprehensive				to China Biologic				Noncontrolling
		shares				Par value				capital				earnings				Stock				income				Products, Inc.				interest				Total equity
						USD				USD				USD				USD				USD				USD				USD				USD
Balance as of January 1, 2014			27,341,744				2,734				72,031,864				173,744,551				(29,594,080	)			21,506,494				237,691,563				66,278,046				303,969,609
Net income			-				-				-				37,998,626				-				-				37,998,626				12,725,584				50,724,210
Other comprehensive income			-				-				-				-				-				(2,109,842	)			(2,109,842	)			(479,598	)			(2,589,440	)
Share repurchase			-				-				-				-				(70,000,000	)			-				(70,000,000	)			-				(70,000,000	)
Share-based compensation			-				-				1,961,929				-				-				-				1,961,929				-				1,961,929
Excess tax benefits from stock option exercises			-				-				629,695				-				-				-				629,695				131,174				760,869
Common stock issued in connection with:
- Exercise of stock options			193,431				19				1,643,540				-				-				-				1,643,559				-				1,643,559
- Vesting of restricted shares			5,625				1				(1	)			-				-				-				-				-				-
Balance as of June 30, 2014			27,540,800				2,754				76,267,027				211,743,177				(99,594,080	)			19,396,652				207,815,530				78,655,206				286,470,736

 

 

 

 

 

 

 

See accompanying notes to Unaudited Condensed Consolidated Financial Statements.

 

 

CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES

UNAUDITED CONDESENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 

 

 

		For the six months ended
		June 30, 2014				June 30, 2013
		USD				USD
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income			50,724,210				44,890,005
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation			3,289,535				3,105,739
Amortization			371,168				702,556
Loss (gain) on sale of property, plant and equipment			71,494				(70,363	)
Provision of doubtful accounts, net			1,477				-
Provision of doubtful accounts - other receivables and prepayments			-				6,202
Write-down of obsolete inventories			9,092				-
Deferred tax expense			1,154,991				720,679
Share-based compensation			1,961,929				3,047,962
Equity in income of an equity method investee			(1,860,579	)			(739,945	)
Excess tax benefits from share-based compensation arrangements			(760,869	)			-
Change in operating assets and liabilities:
Accounts receivable			(7,473,499	)			(6,314,643	)
Prepayment and other assets			(2,393,459	)			(101,135	)
Inventories			(6,852,680	)			(3,616,165	)
Accounts payable			(438,427	)			242,365
Other payables and accrued expenses			(1,287,497	)			(2,033,594	)
Advance from customers			1,693,953				(529,984	)
Due to related parties			(309,859	)			(140,697	)
Income tax payable			1,126,281				(1,260,254	)
Net cash provided by operating activities			39,027,261				37,908,728
CASH FLOWS FROM INVESTING ACTIVITIES:
Payment for property, plant and equipment			(10,243,198	)			(11,912,603	)
Payment for intangible assets and land use right			(1,227,914	)			(1,137,556	)
Dividend received			-				560,980
Refund of deposits related to land use right			1,635,200				-
Proceeds upon maturity of time deposit			6,608,612				-
Proceeds from sale of property, plant and equipment			190,660				83,731
Net cash used in investing activities			(3,036,640	)			(12,405,448	)

 

 

 

 

See accompanying notes to Unaudited Condensed Consolidated Financial Statements.

 

 

CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)

 

 

 

		For the six months ended
		June 30, 2014				June 30, 2013
		USD				USD
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from stock option exercised			1,643,559				2,668,916
Proceeds from short term bank loans			-				4,808,400
Repayment of short term bank loans			(4,905,600	)			(8,014,000	)
Proceeds from long-term bank loans			70,000,000				-
Payment for deposits as security for long-term bank loans			(72,290,922	)			-
Payment for share repurchase			(70,000,000	)			-
Acquisition of noncontrolling interest			-				(1,963,913	)
Excess tax benefits from share-based compensation arrangements			760,869				-
Dividend paid by subsidiaries to noncontrolling interest shareholders			(1,409,542	)			(8,110,168	)
Net cash used in financing activities			(76,201,636	)			(10,610,765	)
EFFECTS OF FOREIGN EXCHANGE RATE CHANGE ON CASH			(703,847	)			2,762,616
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS			(40,914,862	)			17,655,131
Cash and cash equivalents at beginning of period			144,138,487				129,609,317
Cash and cash equivalents at end of period			103,223,625				147,264,448
Supplemental cash flow information
Cash paid for income taxes			7,564,408				8,892,126
Cash paid for interest expense			1,067,251				198,900
Noncash investing and financing activities:
Acquisition of property, plant and equipment included in payables			2,805,220				1,554,828
Transfer from prepayments to property, plant and equipment			727,937				6,815,689

 

 

 

 

See accompanying notes to Unaudited Condensed Consolidated Financial Statements.

 

 

CHINA BIOLOGIC PRODUCTS INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2014 AND 2013

 

NOTE 1 – BASIS OF PRESENTATION, SIGNIFICANT CONCENTRATION AND RISKS

 

(a)

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted by rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The December 31, 2013 consolidated balance sheet was derived from the audited consolidated financial statements of China Biologic Products, Inc. (the “Company”). The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the December 31, 2013 audited consolidated financial statements of the Company included in the Company’s annual report on Form 10-K for the year ended December 31, 2013.

 

In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the financial position as of June 30, 2014, the results of operations for the three and six months ended June 30, 2014 and 2013, and cash flows for the six months ended June 30, 2014 and 2013, have been made. All significant intercompany transactions and balances are eliminated on consolidation.

 

The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the useful lives of property, plant and equipment and intangibles with definite lives, the allowance for doubtful accounts, the fair value determinations of equity instruments and stock compensation awards, the realizability of deferred tax assets and inventories, the recoverability of intangible assets, land use rights and property, plant and equipment, and accruals for income tax uncertainties and other contingencies.

 

(b)

Significant Concentration and Risks

 

The Company’s operations are carried out in the People’s Republic of China (the “PRC”) and are subject to specific considerations and significant risks not typically associated with companies in North America and Western Europe. Accordingly, the Company’s business, financial condition and results of operations may be influenced by the political, economic and legal environment in the PRC, and by the general state of the PRC economy. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other matters.

 

The Company maintains cash and deposit balances at financial institutions which, from time to time, may exceed Federal Deposit Insurance Corporation insured limits for its bank accounts located in the United States or may exceed Hong Kong Deposit Protection Board insured limits for its bank accounts located in Hong Kong. Cash and deposit balances maintained at financial institutions or state-owned banks in the PRC are not covered by insurance. Total cash at banks and deposits as of June 30, 2014 and December 31, 2013 amounted to $205,009,160 and $180,858,848, respectively, of which $250,000 and $679,022 are insured, respectively. The Company has not experienced any losses in uninsured bank deposits and does not believe that it is exposed to any significant risks on cash held in bank accounts.

 

The Company’s two major products are human albumin and human immunoglobulin for intravenous injection (“IVIG”). Human albumin accounted for 34.1% and 42.5% of the total sales for the three months ended June 30, 2014 and 2013, respectively, and 38.1% and 40.2% of the total sales for the six months ended June 30, 2014 and 2013, respectively. IVIG accounted for 44.0% and 39.4% of the total sales for the three months ended June 30, 2014 and 2013, respectively, and 40.4% and 43.5% of the total sales for the six months ended June 30, 2014 and 2013, respectively. If the market demands for human albumin and IVIG cannot be sustained in the future or the price of human albumin and IVIG decreases, the Company’s operating results could be adversely affected.

 

Substantially all of the Company’s customers are located in the PRC. There were no customers that individually comprised 10% or more of the total sales during the three months and six months ended June 30, 2014 and 2013, respectively. No individual customer represented 10% or more of trade receivables at June 30, 2014 and December 31, 2013, respectively. The Company performs ongoing credit evaluations of its customers’ financial condition and, generally, requires no collateral from its customers.

 

There were no suppliers that comprised 10% or more of the total purchases for the three months and six months ended June 30, 2014 and 2013, respectively. No vendors individually represented more than 10% of accounts payable at June 30, 2014 and December 31, 2013, respectively.

 

 

NOTE 2 – ACCOUNTS RECEIVABLE

 

Accounts receivable at June 30, 2014 and December 31, 2013 consisted of the following:

		June 30, 2014				December 31, 2013
		USD				USD
Accounts receivable			25,056,909				17,730,821
Less: Allowance for doubtful accounts			(458,786	)			(460,689	)
Total			24,598,123				17,270,132

 

The activity in the allowance for doubtful accounts for the six months ended June 30, 2014 and 2013 are as follows:

 

		For the six months ended
		June 30, 2014				June 30, 2013
		USD				USD
Beginning balance			460,689				415,607
Provisions			1,477				-
Recoveries			-				-
Write-offs			-				-
Foreign currency translation adjustment			(3,380	)			8,642
Ending balance			458,786				424,249

  

NOTE 3 – INVENTORIES

 

Inventories at June 30, 2014 and December 31, 2013 consisted of the following:

 

		June 30, 2014				December 31, 2013
		USD				USD
Raw materials			47,198,612				47,400,578
Work-in-process			29,083,199				20,720,666
Finished goods			18,530,930				20,513,611
Total			94,812,741				88,634,855

 

No inventory write-down was recorded during the three months ended June 30, 2014 and 2013, respectively. An inventory write-down of 9,092 and nil was recorded for the six months ended June 30, 2014 and 2013, respectively.

 

NOTE 4 – PROPERTY, PLANT AND EQUIPMENT

 

Property, plant and equipment at June 30, 2014 and December 31, 2013 consisted of the following:

 

		June 30, 2014				December 31, 2013
		USD				USD
Buildings			32,064,834				31,714,173
Machinery and equipment			52,265,347				36,919,094
Furniture, fixtures, office equipment and vehicles			7,582,541				8,141,993
Total property, plant and equipment, gross			91,912,722				76,775,260
Accumulated depreciation			(27,550,196	)			(25,658,760	)
Total property, plant and equipment, net			64,362,526				51,116,500
Construction in progress			10,208,944				19,050,642
Prepayment for property, plant and equipment			2,395,373				2,981,930
Property, plant and equipment, net			76,966,843				73,149,072

 

Depreciation expense for the three months ended June 30, 2014 and 2013 was $1,817,138 and $1,571,232, respectively. Depreciation expense for the six months ended June 30, 2014 and 2013 was $3,289,535 and $3,105,739, respectively.

 

NOTE 5 – DEPOSITS RELATED TO LAND USE RIGHTS

 

In 2012, Guizhou Taibang made a refundable payment of RMB83,400,000 (approximately $13,552,500) to the local government in connection with the public bidding for a land use right in Guizhou Province. Given the decrease of the land area to be provided by the local government, RMB23,000,000 (approximately $3,737,500) was refunded by the local government. The remaining deposits will be refunded within one year following the completion of the bidding process.

 

 

NOTE 6 – RESTRICTED CASH AND DEPOSIT

 

On August 7, 2013, the Company made a time deposit of RMB186,000,000 (approximately $30,225,000) with China Merchants Bank Beijing Branch (“CMB BJ Branch”) as a security for an 18-month US$30,000,000 loan lent by China Merchants Bank Co., Ltd., New York Branch (“CMB NY Branch”) (see Note 7). In April 2014, due to the depreciation of RMB against USD, additional deposit of RMB1,000,000 (approximately $162,500) was made as security for this loan.

 

In February 2014, the Company made time deposits of RMB246,500,000 (approximately $40,056,250) and RMB194,600,000 (approximately $31,622,500) with CMB BJ Branch as a security for a 24-month $40,000,000 loan and an 18-month $30,000,000 loan respectively lent by CMB NY Branch (see Note 7).

 

NOTE 7 – BANK LOANS

 

(a)

Current

 

The Company’s bank loans as of June 30, 2014 and December 31, 2013 consisted of the following:

 

		Maturity		Annual				June 30,				December 31,
Loans		date		interest rate				2014				2013
								USD				USD
Short-term bank loan, unsecured		May 12, 2014			6.00%				-				4,911,000
Short-term bank loan, unsecured		December 22, 2014			6.00%				4,875,000				4,911,000
Current portion of long-term bank loans		February 7, 2015			See note (b)				30,000,000				-
Total									34,875,000				9,822,000

 

Interest expense on short-term bank loans was $73,213 and $79,410 for the three months ended June 30, 2014 and 2013, respectively. Interest expense on short-term bank loans was $205,957 and $198,900 for the six months ended June 30, 2014 and 2013, respectively.

 

The Company did not have any revolving line of credit at June 30, 2014.

 

(b)

Non-current

 

		June 30, 2014				December 31, 2013
		USD				USD
Long-term bank loans			100,000,000				30,000,000
Less: current portion of long-term bank loans			30,000,000				-
Total non-current bank loans			70,000,000				30,000,000

 

On August 8, 2013, the Company entered into a credit facility agreement with CMB NY Branch to finance the share repurchase (see Note 15). Pursuant to the facility agreement, CMB NY Branch lends to the Company an 18-month $30,000,000 loan bearing an interest rate of 3-month LIBOR plus 1.6% per annum and a facility fee of 0.7% per annum. The loan is secured by a time deposit of RMB187,000,000 (approximately $30,387,500) held at CMB BJ Branch at June 30, 2014.

 

The Company entered into a credit facility agreement with CMB NY Branch on February 25, 2014. Pursuant to the facility agreement, CMB NY Branch lent to the Company a 24-month $40,000,000 loan and an 18-month $30,000,000 loan, secured by time deposits of RMB246,500,000 (approximately $40,056,250) and RMB194,600,000 (approximately $31,622,500), respectively, held at CMB BJ Branch. Both loans bear an interest rate of 3-month LIBOR plus 1.3% per annum and a facility fee of 1.2% per annum.

 

NOTE 8 – INCOME TAX

 

On October 31, 2011, Shandong Taibang received a notice from the Shandong provincial government that the High and New Technology Enterprise qualification has been renewed for an additional three years which entitled it to a 15% preferential income tax rate from 2011 to 2013. Subject to reapplication, Shandong Taibang’s High-Tech Enterprise status will enable it to continue to enjoy the preferential income tax rate. Management believes that Shandong Taibang meets all the criteria for the reapplication of High-Tech Enterprise status.

 

According to Cai Shui [2011] No. 58 dated July 27, 2011, Guizhou Taibang, being a qualified enterprise located in the western region of PRC, enjoys a preferential income tax rate of 15% effective retroactively from January 1, 2011 to December 31, 2020.

 

The Company’s effective income tax rates were 14% and 14% for the three months ended June 30, 2014 and 2013, respectively. The Company’s effective income tax rates were 16% and 16% for the six months ended June 30, 2014 and 2013, respectively.

 

As of and for the three months ended June 30, 2014, the Company did not have any unrecognized tax benefits and thus no interest and penalties related to unrecognized tax benefits were recorded. In addition, the Company does not expect that the amount of unrecognized tax benefits to change significantly within the next 12 months.

 

 

NOTE 9 – OPTIONS AND NONVESTED SHARES

 

Options

 

A summary of stock options activity for six months ended June 30, 2014 is as follow:

 

		Number of Options				Weighted Average Exercise Price				Weighted Average Remaining Contractual Term in Years				Aggregate Intrinsic Value
						USD								USD
Outstanding at December 31, 2013			1,882,376				9.98				7.20				35,518,897
Granted			-				-
Exercised			(193,431	)			8.50								6,188,171
Forfeited and expired			(21,670	)			12.26
Outstanding at June 30, 2014			1,667,275				10.12				6.90				57,265,302
Vested and expected to vest			1,667,275				10.12				6.90				57,265,302
Exercisable at June 30, 2014			1,192,275				10.28				6.45				40,758,802

 

For the three months ended June 30, 2014 and 2013, the Company recorded stock compensation expense of $427,447 and $1,230,066, respectively, in general and administrative expenses. For the six months ended June 30, 2014 and 2013, the Company recorded stock compensation expense of $854,894 and $2,694,999, respectively, in general and administrative expenses.

 

At June 30, 2014, approximately $2,799,128 of stock compensation expense with respect to the non-vested stock options is expected to be recognized over approximately 1.85 years.

 

Nonvested shares

 

A summary of nonvested shares activity for the six months ended June 30, 2014 is as follows:

 

		Number of nonvested shares				Grant date weighted average fair value
							USD
Outstanding at December 31, 2013			362,750				20.91
Granted			-				-
Vested			(5,625	)			18.58
Forfeited			-				-
Outstanding at June 30, 2014			357,125				20.94

 

For the three months ended June 30, 2014 and 2013, the Company recorded stock compensation expense of $553,517 and $183,161 respectively in general and administrative expenses. For the six months ended June 30, 2014 and 2013, the Company recorded stock compensation expense of $1,107,035 and $352,963 respectively in general and administrative expenses.

 

At June 30, 2014, approximately $5,617,881 of stock compensation expense with respect to nonvested shares is expected to be recognized over approximately 2.75 years.

 

NOTE 10 – FAIR VALUE MEASUREMENTS

 

Management used the following methods and assumptions to estimate the fair value of financial instruments at the relevant balance sheet dates:

 

• Short-term financial instruments (including cash, time deposit, accounts receivable, other receivables, short-term bank loans including current portion of long-term bank loans, accounts payable, other payables and accrued expenses, and amount due to related parties) – The carrying amounts of the short-term financial instruments approximate their fair values because of the short maturity of these instruments.

 

• Restricted cash and deposit – The carrying amounts of the restricted cash and deposit approximate their fair value. The fair value is estimated using discounted cash flow analysis based on the Company’s incremental borrowing rates for similar borrowing.

 

• Long-term bank loan excluding current portion of long-term bank loans– fair value is based on the amount of future cash flows associated with the long-term bank loan discounted at the Company’s current borrowing rate for similar debt instruments of comparable terms. The carrying value of the long-term bank loan approximate its fair value as the long-term bank loan carry variable interest rate which approximate rate currently offered by the Company’s bankers for similar debt instruments of comparable maturities.

 

 

NOTE 11 – SALES

 

The Company’s sales are primarily derived from the manufacture and sale of Human Albumin and Immunoglobulin products. The Company’s sales by significant types of product for the three months ended June 30, 2014 and 2013 are as follows:

 

		For the three months ended
		June 30, 2014				June 30, 2013
		USD				USD
Human Albumin			20,490,892				22,764,711
Immunoglobulin products:
Human Immunoglobulin for Intravenous Injection			26,446,025				21,097,154
Other Immunoglobulin products			4,993,559				5,494,261
Placenta Polypeptide			7,108,510				3,037,991
Others			1,034,998				1,186,406
Total			60,073,984				53,580,523

 

The Company’s sales by significant types of product for the six months ended June 30, 2014 and 2013 are as follows:

 

		For the six months ended
		June 30, 2014				June 30, 2013
		USD				USD
Human Albumin			44,271,893				43,266,022
Immunoglobulin products:
Human Immunoglobulin for Intravenous Injection			46,975,796				46,759,025
Other Immunoglobulin products			13,276,807				10,593,986
Placenta Polypeptide			9,735,063				5,222,154
Others			2,081,002				1,771,068
Total			116,340,561				107,612,255

 

NOTE 12 – COMMITMENTS AND CONTINGENCIES

 

Capital commitments

 

At June 30, 2014, commitments outstanding for the purchase of property, plant and equipment approximated $5,200,000.

 

Legal proceedings

 

Dispute among Guizhou Taibang Shareholders over Raising Additional Capital

 

In May 2007, a 91% majority of Guizhou Taibang’s shareholders approved a plan to raise additional capital from private strategic investors through the issuance of an additional 20,000,000 shares of Guizhou Taibang at RMB2.80 per share. The plan required all existing Guizhou Taibang shareholders to waive their rights of first refusal to subscribe for the additional shares. The remaining 9% minority shareholder of Guizhou Taibang’s shares, Guizhou Jie’an Company, or Jie’an, did not support the plan and did not waive its right of first refusal. In May 2007, the majority shareholders caused Guizhou Taibang to sign an Equity Purchase Agreement with certain investors, pursuant to which the investors agreed to invest an aggregate of $7,475,832 (or RMB50,960,000) in exchange for 18,200,000 shares, or 21.4%, of Guizhou Taibang’s equity interests. At the same time, Jie’an also subscribed for 1,800,000 shares, representing its pro rata share of the 20,000,000 shares being offered. The proceeds from all parties were received by Guizhou Taibang in accordance with the agreement.

 

In June 2007, Jie’an brought suit in the High Court of Guizhou province, China, against Guizhou Taibang and the three other original shareholders of Guizhou Taibang, alleging the illegality of the Equity Purchase Agreement. In its complaint, Jie’an claimed that it had a right to acquire the 18,200,000 shares offered to the strategic investors under the Equity Purchase Agreement. In September 2008, the Guizhou High Court ruled against Jie’an and sustained the Equity Purchase Agreement. In November 2008, Jie’an appealed the Guizhou High Court judgment to the People’s Supreme Court in Beijing. In May 2009, the People’s Supreme Court sustained the original ruling and denied the rights of first refusal of Jie’an over the 18,200,000 shares.

 

 

During the second quarter of 2010, Jie’an requested that Guizhou Taibang register its 1.8 million shares of additional capital injection with the local Administration for Industry and Commerce, or AIC, pursuant to the Equity Purchase Agreement, and such request was approved by the majority shareholders of Guizhou Taibang in a shareholders meeting held in the second quarter of 2010. However, the Board of Directors of the Company is withholding its required ratification of the shareholders’ approval of Jie’an’s request, pending the outcome of the ongoing litigation. In March 2012, the Company received a subpoena that Jie’an brought suit in the People’s Court of Huaxi District, Guizhou Province, against Guizhou Taibang, alleging Guizhou Taibang’s withholding of its request. Jie’an requested that Guizhou Taibang register its 1.8 million shares of capital injection, pay dividends associated with these shares, as well as the related interest and penalty from May 2007 to December 2011 amounting to $3,967,500 (or RMB25,000,000) in aggregate, and return the over-paid subscription of $228,528 (or RMB1,440,000), as well as the interest and penalty, amounting to $1,587,000 (or RMB10,000,000) in aggregate. The People’s Court of Huaxi District, Guizhou Province, has accepted Jie’an’s suit. In May 2012, Guizhou Taibang was informed by the court that the case was postponed upon the request from Jie’an. In July 2013, the People’s Court of Huaxi District issued an order declaring that the suit shall be set aside because the court has no jurisdiction over the suit. Jie’an did not appeal the case to the upper-level court.

 

In December 2013, Jie’an brought suit again in the People’s Court of Huaxi District, Guizhou Province, against Guizhou Taibang, alleging that Guizhou Taibang withheld Jie’an’s request to register 1.8 million shares under its name with the local AIC. The People’s Court of Huaxi District, Guizhou Province, accepted Jie’an’s suit and heard the case on February 26, 2014. In July 2014, the People’s Court of Huaxi District ruled against Jie’an, denying its request to register such shares. However, as part of its ruling, the People’s Court of Huaxi District ordered the Company to pay dividends of $2,240,542 (or RMB 13,809,197) associated with these shares and the related interest expenses to Jie’an. Both the Company and Jie’an appealed the case to the upper-level court in July 2014. As this case should be closely tied to the outcome of the strategic investors' dispute stated below, the Company does not expect Jie'an to prevail.

 

In November 2013, Guizhou Taibang held a shareholders meeting and the shareholders passed resolutions, or the Resolutions, that, inter alia, (i) determined that it was no longer necessary for Guizhou Taibang to obtain additional capital from investors; (ii) rejected Jie'an's request that Jie'an subscribe for additional shares of Guizhou Taibang alone and one or more other shareholders reduce their shareholding in Guizhou Taibang; and (iii) approved the issuance of a total of 20,000,000 new shares to all existing shareholders on a pro rata basis. In December 2013, in addition to its lawsuit against Guizhou Taibang for Guizhou Taibang's failure to register its purchase of 1,800,000 shares in 2007 with the local AIC before the People's Court of Huaxi District, Guiyang, Jie'an filed another lawsuit against Guizhou Taibang with the People’s Court of Huaxi District and requested that the court declare the Resolutions void. The case was heard on March 6, 2014. In July 2014, the People’s Court of Huaxi District ruled against Jie’an denying its request to declare the Resolutions void. Jie’an appealed the case to the upper-level court on July 28, 2014. The Company does not expect Jie'an to prevail.

 

If the Company decides to ratify the approval or the case is ruled in Jie’an’s favor, Dalin’s ownership in Guizhou Taibang will be diluted from 54% to 52.54% and Jie’an may be entitled to receive its pro rata share of Guizhou Taibang’s profits since the date on which Jie’an’s capital contribution became effective. As this case is closely tied to the outcome of the strategic investors’ dispute stated below, the Company does not expect Jie’an to prevail. As of June 30, 2014, the Company had recorded, in its balance sheet, payables to Jie’an in the amounts of RMB5,040,000 (approximately $819,000) for the additional funds received in relation to the 1.8 million shares of capital infusion, RMB1,440,000 (approximately $234,000) for the over-paid subscription and RMB3,135,095 (approximately $509,453) for the accrued interest.

 

As a result of this dispute, the strategic investors’ equity ownership in Guizhou Taibang and the related increase in registered capital of Guizhou Taibang have not been registered with the local AIC. In January 2010, the strategic investors brought suit in the High Court of Guizhou Province against Guizhou Taibang alleging Guizhou Taibang’s failure to register their equity interest in Guizhou Taibang with the local AIC and requesting the distribution of their share of Guizhou Taibang’s dividends declared since 2007. Dalin was also joined as a co-defendant as it is the majority shareholder and exercises control over Guizhou Taibang’s day-to-day operations.

 

In October, 2010, the High Court of Guizhou ruled in favor of the Company and denied the strategic investors’ right as shareholders of Guizhou Taibang, as well as their entitlement to the dividends. In light of this ruling, the Company returned the proceeds of $1,699,040 (or RMB11,200,000) to one of the strategic investors in November 2010. In October 2010, the other strategic investors appealed to the PRC Supreme Court in Beijing on the ruling of the High Court of Guizhou. The PRC Supreme Court overruled the decision of the High Court of Guizhou and remanded the case to the High Court of Guizhou for retrial. In January 2012, the strategic investors re-filed their case to the High Court of Guizhou requesting, in addition to the share distribution, the distribution of dividends and interest in the amount of RMB18,349,345 (approximately $2,981,769) and RMB2,847,000 (approximately $462,638), respectively. In December 2012, the High Court of Guizhou affirmed the judgment against the strategic investors. In January 2013, the strategic investors appealed to the PRC Supreme Court on the ruling again and the appeal was accepted.

 

In September 2013, the PRC Supreme Court made the final judgment against the strategic investors and denied the strategic investors’ right as shareholders of Guizhou Taibang and their claim for the related dividend distribution. In November 2013, the strategic investors requested the PRC Supreme Court to reconsider the judgment and such request was rejected by the PRC Supreme Court on January 17, 2014. As of June 30, 2014, Guizhou Taibang had made provision for the strategic investors’ initial fund along with RMB18,387,378 (approximately $2,987,949) in accrued interest, and RMB509,600 (approximately $82,810) for the 1% penalty imposed by the agreement for any breach in the event that Guizhou Taibang is required to return their original investment amount to the strategic investors.

 

In April 2013, the Company countersued the strategic investors in the Intermediate Court of Guiyang City alleging their breach of the Security Law in the PRC and requested a consideration of $6,064,800 (or RMB38,000,000) for the related expenses and losses, and Guizhou Intermediate Court accepted the case. In November 2013, the Company withdrew this suit as part of its claims therein had been affirmed in the rulings of the PRC Supreme Court.

 

 

NOTE 13 – RELATED PARTY TRANSACTIONS

 

The material related party transactions undertaken by the Company with related parties for the three months ended June 30, 2014 and 2013 are presented as follows:

 

 

		For the three months ended
		June 30, 2014				June 30, 2013
		USD				USD
Commission expenses with related parties(1)			1,450,921				909,057

 

The material related party transactions undertaken by the Company with related parties for the six months ended June 30, 2014 and 2013 are presented as follows:

 

		For the six months ended
		June 30, 2014				June 30, 2013
		USD				USD
Commission expenses with related parties(1)			2,249,716				1,552,312

 

The related party balances as at June 30, 2014 and December 31, 2013 are presented as follows:

 

Liabilities		Purpose		June 30, 2014				December 31, 2013
				USD				USD
Other payable – a related party(1)		Commission			8,125				351,955
Other payable – a related party(2)		Loan			2,366,000				2,383,472
Other payable – a related party(3)		Contribution			2,908,425				2,929,903
Other payable – related parties(4)		Contribution			1,562,453				1,541,640
Total other payable – related parties					6,845,003				7,206,970

 

 

(1)

During the year ended December 31, 2011, Guizhou Taibang signed an agency contract with Guizhou Eakan Co., Ltd. (“Guizhou Eakan”), an affiliate of one of the Guizhou Taibang’s noncontrolling interest shareholders, pursuant to which Guizhou Taibang would pay commission to Guizhou Eakan for the promotion of the product of Placenta Polypeptide. At June 30, 2014 and December 31, 2013, Guizhou Taibang accrued commission payable of $8,125 and $351,955 for service rendered by Guizhou Eakan, respectively. For the three months ended June 30, 2014 and 2013, commission expense for service rendered by Guizhou Eakan was $1,450,921 and $909,057, respectively. For the six months ended June 30 , 2014 and 2013, commission expense for service rendered by Guizhou Eakan was $2,249,716 and $1,552,312, respectively. The agency contract expired on May 31, 2014 and Guizhou Eakan no longer provided the promotion services thereafter.

 

(2)

Guizhou Taibang has payables to Guizhou Eakan Investing Corp., amounting to approximately $2,366,000 and $2,383,472 at June 30, 2014 and December 31, 2013, respectively. Guizhou Eakan Investing Corp. is one of the noncontrolling interest shareholders of Guizhou Taibang. The Company borrowed this interest free advance for working capital purpose for Guizhou Taibang. The balance is due on demand.

 

(3)

In December 2013, Guizhou Taibang received a contribution of RMB17,898,000 (approximately $2,908,425) from Guizhou Eakan Investing Corp. pending for the registration with the local AIC.

 

(4)

Guizhou Taibang has payables to Jie’an, a noncontrolling interest shareholder of Guizhou Taibang, amounting to approximately $1,562,453 and $1,541,640 at June 30, 2014 and December 31, 2013, respectively. In 2007, Guizhou Taibang received additional contributions from Jie’an of $962,853 (or RMB6,480,000) to maintain Jie’an’s equity interest in Guizhou Taibang at 9%. However, due to a legal dispute among shareholders over raising additional capital as discussed in the legal proceeding section (see Note 12), the contribution is subject to be returned to Jie’an. During the second quarter of 2010, Jie’an requested that Guizhou Taibang register its 1.8 million shares of additional capital contribution with the local AIC, pursuant to the Equity Purchase Agreement, and such registration was approved by the majority shareholders of Guizhou Taibang in a shareholders’ meeting held in the second quarter of 2010. However, the Board of Directors of the Company is withholding its required ratification of the shareholders’ approval of Jie’an’s request until the completion of the ongoing litigations. If the Company decided to ratify the approval, Dalin’s ownership in Guizhou Taibang will be diluted from 54% to 52.54% and Jie’an will be entitled to receive its pro rata share of Guizhou Taibang’s profits since the date on which Jie’an’s contribution became effective. As this case is closely tied to the outcome of the strategic investors’ dispute stated above, the Company has recorded, in its balance sheet, payables to Jie’an in the amounts of RMB5,040,000 (approximately $819,000) for the additional funds received in relation to the 1.8 million shares of capital infusion, RMB1,440,000 (approximately $234,000) for the over-paid subscription and RMB3,135,095 (approximately $509,453) for the accrued interest and penalty at June 30, 2014.

 

 

 

NOTE 14 - NET INCOME PER SHARE

 

The following table sets forth the computation of basic and diluted net income per share for the periods indicated:

 

		For the three months ended
		June 30, 2014				June 30, 2013
		USD				USD
Net income attributable to China Biologic Products, Inc.			19,724,955				16,161,926
Earnings allocated to participating nonvested shares			(295,479	)			(85,227	)
Net income used in basic/diluted net income per common stock			19,429,476				16,076,699
Weighted average shares used in computing basic net income per common stock			23,483,090				26,880,459
Diluted effect of stock option			1,235,921				1,186,844
Weighted average shares used in computing diluted net income per common stock			24,719,011				28,067,303
Net income per common stock – basic			0.83				0.60
Net income per common stock – diluted			0.79				0.57

 

During the three months ended June 30, 2014 and 2013, no option was antidilutive and excluded from the calculation of diluted net income per common stock.

 

The following table sets forth the computation of basic and diluted net income per share for the periods indicated:

 

		For the six months ended
		June 30, 2014				June 30, 2013
		USD				USD
Net income attributable to China Biologic Products, Inc.			37,998,626				31,077,786
Earnings allocated to participating nonvested shares			(554,349	)			(157,615	)
Net income used in basic/diluted net income per common stock			37,444,277				30,920,171
Weighted average shares used in computing basic net income per common stock			24,212,766				26,833,262
Diluted effect of stock option			1,222,356				1,133,818
Weighted average shares used in computing diluted net income per common stock			25,435,122				27,967,080
Net income per common stock – basic			1.55				1.15
Net income per common stock – diluted			1.47				1.11

 

During the six months ended June 30, 2014 and 2013, no option was antidilutive and excluded from the calculation of diluted net income per common stock.

 

NOTE 15 – SHARE REPURCHASE

 

On January 27, 2014, the Company entered into a redemption agreement with one of its individual shareholders, pursuant to which the Company repurchased 2,500,000 shares of common stock for a consideration of $70,000,000. The transaction was completed on February 28, 2014.

 

NOTE 16 – SUBSEQUENT EVENT

 

On July 2, 2014, the Company completed a follow-on offering of 1,782,500 shares of common stock at a price of $38.00 per share, less the underwriting discounts. In this offering, the Company sold 920,000 shares (including 120,000 shares sold pursuant to the exercise by the underwriters of their option to purchase additional shares from the Company) and a selling stockholder sold 862,500 shares (including 112,500 shares sold pursuant to the exercise by the underwriters of their option to purchase additional shares from such selling stockholder). The Company raised net proceeds of approximately $33.2 million from this offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company did not receive any proceeds from the sale of the shares by the selling stockholder.

 

  

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

Special Note Regarding Forward Looking Statements

 

In addition to historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We use words such as “believe,” “expect,” “anticipate,” “project,” “target,” “plan,” “optimistic,” “intend,” “aim,” “will” or similar expressions which are intended to identify forward-looking statements. Such statements include, among others, those concerning market and industry segment growth and demand and acceptance of new and existing products; expectations regarding governmental approvals of our new products; any projections of sales, earnings, revenue, margins or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements regarding future economic conditions or performance; as well as all assumptions, expectations, predictions, intentions or beliefs about future events. You are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those identified in Item 1A “Risk Factors” described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, as well as assumptions, which, if they were to ever materialize or prove incorrect, could cause the results of the Company to differ materially from those expressed or implied by such forward-looking statements.

 

Readers are urged to carefully review and consider the various disclosures made by us in this report and our other filings with the SEC. These reports attempt to advise interested parties of the risks and factors that may affect our business, financial condition and results of operations and prospects. The forward-looking statements made in this report speak only as of the date hereof and we disclaim any obligation, except as required by law, to provide updates, revisions or amendments to any forward-looking statements to reflect changes in our expectations or future events.

 

Use of Terms

 

Except as otherwise indicated by the context and for the purposes of this report only, references in this report to:

 

·

“China Biologic”, the “Company”, “we”, “us”, or “our”, are to the combined business of China Biologic Products, Inc., a Delaware corporation, and its direct and indirect subsidiaries;

·

“Taibang Biological” are to our wholly owned subsidiary Taibang Biological Limited, a BVI company, formerly Logic Express Limited;

·

“Taibang Holdings” are to our wholly owned subsidiary Taibang Holdings (Hong Kong) Limited, a Hong Kong company, formerly Logic Holdings (Hong Kong) Limited;

·

“Taibang Biotech” are to our wholly owned subsidiary Taibang Biotech (Shandong) Co., Ltd., a PRC company, formerly Logic Management and Consulting (China) Co., Ltd.;

·

“Taibang Beijing” are to our wholly owned subsidiary Taibang (Beijing) Pharmaceutical Research Institute Co., Ltd., a PRC company, formerly Logic Taibang Biotech Institute (Beijing);

·

“Dalin” are to our wholly owned subsidiary Guiyang Dalin Biologic Technologies Co., Ltd., a PRC company;

·

“Shandong Taibang” are to our majority owned subsidiary Shandong Taibang Biological Products Co. Ltd., a sino-foreign joint venture incorporated in China;

·

“Taibang Medical” are to our wholly owned subsidiary Shandong Taibang Medical Company, a PRC company;

·

“Guizhou Taibang” are to our majority owned subsidiary Guizhou Taibang Biological Products Co., Ltd., a PRC company, formerly Guiyang Qianfeng Biological Products Co., Ltd.;

·

“Huitian” are to our minority owned investee Xi’an Huitian Blood Products Co., Ltd., a PRC company;

·

“Board” are to our board of directors;

·

“BVI” are to the British Virgin Islands;

·

“Hong Kong” are to the Hong Kong Special Administrative Region of the People’s Republic of China;

·

“PRC” and “China” are to the People’s Republic of China;

·

“SEC” are to the Securities and Exchange Commission;

·

“Securities Act” are to the Securities Act of 1933, as amended;

·

“Exchange Act” are to the Securities Exchange Act of 1934, as amended;

·

“Renminbi” and “RMB” are to the legal currency of China;

·

“U.S. dollars”, “USD” and “$” are to the legal currency of the United States; and

·

“New GMP Standard” are to the Drug Good Manufacturing Practice Regulations enacted by the PRC Ministry of Health on February 12, 2001 and the Good Manufacturing Practice Implementation Guidelines published by the China Food and Drug Administration on February 24, 2011.

 

  

Overview of Our Business

 

We are a biopharmaceutical company principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products, or plasma products, in China. We operate our business through two majority owned subsidiaries, Shandong Taibang, a company based in Tai’an, Shandong Province and Guizhou Taibang, a company based in Guiyang, Guizhou Province. We also hold a minority equity interest in Huitian, a company based in Xi’an, Shaanxi Province.

 

We have a strong product portfolio with over 20 different dosage forms of plasma products. Our principal products are human albumin and immunoglobulin for intravenous injection, or IVIG. Albumin has been used for almost 50 years to treat critically ill patients by assisting the maintenance of adequate blood volume and pressure. IVIG is used for certain disease prevention and treatment by enhancing specific immunity. These products use human plasma as their principal raw material. Sales of human albumin products represented approximately 34.1% and 42.5% of our total sales for the three months ended June 30, 2014 and 2013, respectively, and 38.1% and 40.2% of our total sales for the six months ended June 30, 2014 and 2013, respectively. Sales of IVIG products represented approximately 44.0% and 39.4% of our total sales for the three months ended June 30, 2014 and 2013, respectively, and 40.4% and 43.5% of our total sales for the six months ended June 30, 2014 and 2013, respectively. All of our products are prescription medicines administered in the form of injections.

 

Our sales model focuses on direct sales to hospitals and inoculation centers and is complemented by distributor sales. We usually sign short-term contracts with customers and therefore our largest customers have changed over the years. For the three months ended June 30, 2014 and 2013, our top five customers accounted for approximately 12.3% and 13.9%, respectively, of our total sales. For the six months ended June 30, 2014 and 2013, our top five customers accounted for approximately 17.7% and 10.5%, respectively, of our total sales. As we continue to expand our geographic presence and diversify our customer base and product mix, we expect that our largest customers will continue to change from year to year.

 

We operate and manage our business as a single segment. We do not account for the results of our operations on a geographic or other basis.

 

Our principal executive offices are located at 18^th Floor, Jialong International Building, 19 Chaoyang Park Road, Chaoyang District, Beijing 100125, the People’s Republic of China. Our corporate telephone number is + (86) 10-6598-3111 and our fax number is + (86) 10-6598-3222. We maintain a website at http://www.chinabiologic.com, which contains information about the Company, but that information is not part of this report.

 

Recent Developments

 

In June 2014, the China Food and Drug Administration, or CFDA, conducted an on-site inspection on our new factor production facility at Shandong Taibang. Shandong Taibang expects to obtain the GMP certification and commence the commercial production at this production facility in the early fourth quarter of 2014.

 

On June 18, 2014, the PRC Ministry of Finance and the PRC State Administration of Taxation jointly published a notice to reduce and unify the value added tax, or VAT, rate on sales of a wide range of products in China, which will take effect on July 1, 2014. Pursuant to the notice, the VAT rate on sales of human blood and blood component based biopharmaceutical products will be reduced from the current rate of 6% to 3%. We believe that the reduction in VAT rate will be applicable to and will have a favorable impact on the sales of all plasma products of Shandong Taibang and Guizhou Taibang. Although we are still assessing the quantitative impact of this favorable VAT reduction on our future results of operation, we expect that once implemented this reduction in the VAT rate will have a positive impact on our sales and net income in the second half of 2014 and onwards as our sales revenue is recognized as the invoiced value of products sold minus VAT.

 

On July 2, 2014, we completed a follow-on offering of 1,782,500 shares of common stock at a price of $38.00 per share, less the underwriting discounts. In this offering, we sold 920,000 shares (including 120,000 shares sold pursuant to the exercise by the underwriters of their option to purchase additional shares from us) and a selling stockholder sold 862,500 shares (including 112,500 shares sold pursuant to the exercise by the underwriters of their option to purchase additional shares from such selling stockholder). We raised net proceeds of $33.2 million from this offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. We did not receive any proceeds from the sale of the shares by the selling stockholder.

 

Second Quarter Financial Performance Highlights

 

The following are some financial highlights for the three months ended June 30, 2014:

 

·

Sales: Sales increased by $6.5 million, or 12.1%, to $60.1 million for the three months ended June 30, 2014, from $53.6 million for the same period in 2013.

 

  

·

Gross profit: Gross profit increased by $3.7 million, or 9.9%, to $41.2 million for the three months ended June 30, 2014, from $37.5 million for the same period in 2013.

 

·

Income from operations: Income from operations increased by $3.6 million, or 14.2%, to $28.9 million for the three months ended June 30, 2014, from $25.3 million for the same period in 2013.

 

·

Net income attributable to the Company: Net income increased by $3.5 million, or 21.6%, to $19.7 million for the three months ended June 30, 2014, from $16.2 million for the same period in 2013.

 

·

Diluted net income per share: Diluted net income per share was $0.79 for the three months ended June 30, 2014, as compared to $0.57 for the same period in 2013.

 

Results of Operations

 

Comparison of Three Months Ended June 30, 2014 and June 30, 2013

 

The following table sets forth key components of our results of operations in thousands of U.S. dollars for the periods indicated.

 

		For the three months ended June 30,
		2014								2013
		Amount				% of Total Sales				Amount				% of Total Sales
		(U.S. dollars in thousands, except percentage)
Sales			60,074				100.0				53,581				100.0
Cost of sales			18,920				31.5				16,123				30.1
Gross margin			41,154				68.5				37,458				69.9
Operating expenses:
Selling expenses			3,329				5.5				2,442				4.6
General and administrative expenses			7,113				11.8				8,866				16.5
Research and development expenses			1,839				3.1				835				1.6
Total operating expenses			12,281				20.4				12,143				22.7
Income from operations			28,873				48.1				25,315				47.2
Other income (expenses):
Equity in income of an equity method investee			1,523				2.4				611				1.2
Interest expense			(863	)			(1.4	)			(199	)			(0.4	)
Interest income			1,725				2.9				996				1.9
Total other income, net			2,385				3.9				1,408				2.7
Earnings before income tax expense			31,258				52.0				26,723				49.9
Income tax expense			4,486				7.5				3,745				7.0
Net income			26,772				44.5				22,978				42.9
Less: Net income attributable to noncontrolling interest			7,047				11.7				6,816				12.7
Net income attributable to the Company			19,725				32.8				16,162				30.2
Net income per share of common stock
Basic			0.83								0.60
Diluted			0.79								0.57

 

Sales

 

Our sales increased by $6.5 million, or 12.1%, to $60.1 million for the three months ended June 30, 2014, compared to $53.6 million for the same period in 2013. The increase in sales for the three months ended June 30, 2014 was primarily attributable to the sales volume increases in certain plasma products and placenta polypeptide product.

 

 

 

The following table summarizes the breakdown of sales by significant types of product:

 

		For the three months ended June 30,																Change
		2014								2013
		Amount				%				Amount				%				Amount				%
		(U.S. dollars in millions, except percentage)
Human Albumin			20.5				34.1				22.8				42.5				(2.3	)			(10.1	)
Immunoglobulin products:
IVIG			26.4				44.0				21.1				39.4				5.3				25.1
Other Immunoglobulin products			5.0				8.3				5.5				10.3				(0.5	)			(9.1	)
Placenta Polypeptide			7.1				11.8				3.0				5.6				4.1				136.7
Others			1.1				1.8				1.2				2.2				(0.1	)			(8.3	)
Totals			60.1				100.0				53.6				100.0				6.5				12.1

 

During the three months ended June 30, 2014 as compared to the three months ended June 30, 2013:

 

·

the average price for our approved human albumin products, which accounted for 34.1% of our total sales for the three months ended June 30, 2014, decreased slightly by approximately 0.7%, and excluding the foreign exchange translation effect, their average price in RMB term decreased by approximately 1.4%; and

 

·

the average price for our approved IVIG products, which accounted for 44.0% of our total sales for the three months ended June 30, 2014, decreased by approximately 2.2%, and excluding the foreign exchange translation effect, their average price in RMB term decreased by approximately 2.7%.

 

To improve brand recognition during the three months ended June 30, 2014, we increased the market share of our human albumin products and IVIG products in tier one cities through distributors by lowering sales prices, resulting in a decline on the average sales prices of these products.

 

The sales volume of our products depends on market demand and our production volume. The production volume of our human albumin products and IVIG products depends primarily on the general plasma supply. The production volume of our hyper-immune products, which include human rabies immunoglobulin, human hepatitis B immunoglobulin and human tetanus immunoglobulin products, is subject to the availabilities of specific vaccinated plasma and our production capacity. The supply of specific vaccinated plasma requires several months of lead time. Our production facility currently can only accommodate the production of one type of hyper-immune products at any given time and we rotate the production of different types of hyper-immune products from time to time in response to market demand. As such, the sales volume of any given type of hyper-immune products may vary significantly from quarter to quarter.

 

The sales volume of our human albumin products decreased by 9.4% in the three months ended June 30, 2014 as compared to the same period in 2013. The decrease in sales volume of human albumin products was primarily due to the decreased sales volume at Guizhou Taibang, partially offset by the increased sales volume at Shandong Taibang. The decrease in the sales volume at Guizhou Taibang was primarily due to the depletion of its inventory of finished products as most of newly produced albumin products were still awaiting government batch approval after Guizhou Taibang resumed production in March 2014. We expect our sales volume at Guizhou Taibang to rebound in the third quarter of 2014 after new batches of products are approved. The sales volume of our IVIG products increased by 28.2% in the three months ended June 30, 2014 as compared to the same period in 2013. The increase in sales volume of IVIG was primarily due to the increased sales through distributors in tier-one cities. In addition, the outbursts of the Hand-Foot-and-Mouth Disease, or HFMD, during the three months ended June 30, 2014 also contributed to the increase in the sales volume of IVIG during this period as compared to the same period in 2013.

 

The sales increase of placenta polypeptide products was mainly in line with the volume increase for the three months ended June 30, 2014 as compared to the same period in 2013. The sales volume of placenta polypeptide products increased by 137% for the three months ended June 30, 2014 as compared to the same period in 2013. This increase was due to the expanded production of placenta polypeptide at Guizhou Taibang after its receipt of the GMP certification for the upgraded production facilities of placenta polypeptide in January 2014.

 

Cost of sales & gross profit

		For the three months ended June 30,								Change
		2014				2013				Amount				%
		(U.S. dollars in millions, except percentage)
Cost of sales			18.9				16.1				2.8				17.4	%
as a percentage of total sales			31.5	%			30.1	%							1.4	%
Gross Profit			41.2				37.5				3.7				9.9	%
Gross Margin			68.5	%			69.9	%							(1.4	)%

 

  

Our cost of sales was $18.9 million, or 31.5% of our sales for the three months ended June 30, 2014, as compared to $16.1 million, or 30.1% of our sales for the same period in 2013. Our gross profit was $41.2 million and $37.5 million for the three months ended June 30, 2014 and 2013, respectively, representing gross margins of 68.5% and 69.9%, respectively.  Our cost of sales and gross margin are affected by the volume and pricing of our sold products, raw material costs, production mix and respective yields, inventory provisions, production cycles and routine maintenance costs.

 

The increase in cost of sales in the three month ended June 30, 2014 as compared to the same period in 2013 was largely in line with the increases in sales volume and cost of plasma. In an effort to increase plasma collection volume and expand our donor base, we increased the nutrition fees paid to donors consistent with the industry practice. We expected the nutrition fees to be paid to donors continue to increase as a result of improving living standards in China. Consequently, future improvements on margins will need to be derived from increases in product pricing and volume, product mix, yields and manufacturing efficiency. The increase in cost of sales as a percentage of sales in the three month ended June 30, 2014 as compared to the same period in 2013 was mainly due to the increase in cost of plasma partially offset by the change of our product mix to include products with higher margins.

 

Operating expenses

 

		For the three months ended June 30,								Change
		2014				2013				Amount				%
		(U.S. dollars in millions, except percentage)
Operating expenses			12.3				12.1				0.2				1.7	%
as a percentage of total sales			20.4	%			22.7	%							(2.3	)%

 

Our total operating expenses increased by $0.2 million, or 1.7%, to $12.3 million for the three months ended June 30, 2014, from $12.1 million for the same period in 2013. As a percentage of sales, total expenses decreased by 2.3% to 20.4% for the three months ended June 30, 2014, from 22.7% for the same period in 2013. The increase of the total operating expenses was primarily due to the increase of the selling expenses and research and development expenses, partially offset by the decrease of the general and administrative expenses as discussed below.

 

Selling expenses

 

		For the three months ended June 30,								Change
		2014				2013				Amount				%
		(U.S. dollars in millions, except percentage)
Selling expenses			3.3				2.4				0.9				37.5	%
as a percentage of total sales			5.5	%			4.6	%							0.9	%

 

Our selling expenses increased by $0.9 million, or 37.5%, to $3.3 million for the three months ended June 30, 2014, from $2.4 million for the same period in 2013. As a percentage of sales, our selling expenses for the three months ended June 30, 2014 increased by 0.9% to 5.5%, from 4.6% for the same period in 2013. The increase was mainly due to the increased sales of placenta polypeptide for the three months ended June 30, 2014 as compared to the same period in 2013. Compared with other products, placenta polypeptide has a relatively higher per unit selling expenses.

 

General and administrative expenses

		For the three months ended June 30,								Change
		2014				2013				Amount				%
		(U.S. dollars in millions, except percentage)
General and administrative expenses			7.1				8.9				(1.8	)			(20.2	)%
as a percentage of total sales			11.8	%			16.5	%							(4.7	)%

 

Our general and administrative expenses decreased by $1.8 million, or 20.2%, to $7.1 million for the three months ended June 30, 2014, from $8.9 million for the same period in 2013. General and administrative expenses as a percentage of sales decreased by 4.7% to 11.8% for the three months ended June 30, 2014, from 16.5% for the same period in 2013. The decrease in general and administrative expenses was mainly due to a decrease in legal expenses. For the three months ended June 30, 2013, we incurred legal expenses in relation to the take-over defense against one of our direct competitors in China. We did not incur similar legal expenses in the three months ended June 30, 2014. In addition, we incurred amortization expenses in the three months ended June 30, 2013 with respect to the GMP certificates and certain other intangible assets which were part of our acquisition of Guizhou Taibang in 2008. Because such intangible assets had been fully amortized by the end of 2013, we did not incur corresponding expenses in the three months ended June 30, 2014.

 

  

Research and development expenses

		For the three months ended June 30,								Change
		2014				2013				Amount				%
		(U.S. dollars in millions, except percentage)
Research and development expenses			1.8				0.8				1.0				125.0	%
as a percentage of total sales			3.1	%			1.6	%							1.5	%

 

Our research and development expenses increased by $1.0 million, or 125.0%, to $1.8 million for the three months ended June 30, 2014, from $0.8 million for the same period in 2013. As a percentage of sales, our research and development expenses for the three months ended June 30, 2014 and 2013 were 3.1% and 1.6%, respectively. The increase in research and development expenses was mainly due to the expenditure paid for certain clinical trial programs and the engagement of external experts for certain pipeline products for the three months ended June 30, 2014.

 

Income tax

		For the three months ended June 30,								Change
		2014				2013				Amount				%
		(U.S. dollars in millions, except percentage)
Income tax			4.5				3.7				0.8				21.6	%
as a percentage of total sales			7.5	%			7.0	%							0.5	%

 

Our provision for income taxes increased by $0.8 million, or 21.6%, to $4.5 million for the three months ended June 30, 2014, from $3.7 million for the same period in 2013. Our effective income tax rates were 14.4% and 14.0% for the three months ended June 30, 2014 and 2013, respectively. The effective income tax rate remained consistent for the three months ended June 30, 2014 and 2013. Tax rate applicable to our major operating subsidiaries in the PRC for 2014 and 2013 is 15%.

 

Comparison of Six Months Ended June 30, 2014 and June 30, 2013

 

The following table sets forth key components of our results of operations in thousands of U.S. dollars for the periods indicated.

 

		For the six months ended June 30,
		2014								2013
		Amount				% of Total Sales				Amount				% of Total Sales
		(U.S. dollars in thousands, except percentage)
Sales			116,341				100.0				107,612				100.0
Cost of sales			36,636				31.5				32,739				30.4
Gross margin			79,705				68.5				74,873				69.6
Operating expenses:
Selling expenses			5,612				4.8				4,278				4.0
General and administrative expenses			14,329				12.3				17,553				16.3
Research and development expenses			2,912				2.5				1,748				1.6
Total operating expenses			22,853				19.6				23,579				21.9
Income from operations			56,852				48.9				51,294				47.7
Other income (expenses):
Equity in income of an equity method investee			1,861				1.6				740				0.7
Interest expense			(1,484	)			(1.3	)			(435	)			(0.4	)
Interest income			3,320				2.8				1,644				1.5
Total other income, net			3,697				3.1				1,949				1.8
Earnings before income tax expense			60,549				52.0				53,243				49.5
Income tax expense			9,825				8.4				8,353				7.8
Net income			50,724				43.6				44,890				41.7
Less: Net income attributable to noncontrolling interest			12,725				10.9				13,812				12.8
Net income attributable to the Company			37,999				32.7				31,078				28.9
Net income per share of common stock
Basic			1.55								1.15
Diluted			1.47								1.11

 

  

Sales

 

Our sales increased by $8.7 million, or 8.1%, to $116.3 million for the six months ended June 30, 2014, compared to $107.6 million for the same period in 2013. Such increase of sales was mainly due to the increase in sales by Shandong Taibang for the six months ended June 30, 2014, partially offset by the reduced sales volume as a result of the planned production suspension at Guizhou Taibang. The increased sales volume of placenta polypeptide products also contributed to the sales increase. The increased sales by Shandong Taibang were attributable to a combined effect of price and volume increases of certain plasma products during this period. On the other hand, Guizhou Taibang reduced the sales volume of its plasma products during this period to address the impact of the reduced production volume and maintain its sales channels and customer relationships during the period of production suspension. Guizhu Taibang suspended its production since June 2013 for GMP upgrades and resumed commercial production in March 2014. In addition, foreign exchange translation accounted for 1.7% of the sales increase.

 

The following table summarizes the breakdown of sales by significant types of product:

 

		For the six months ended June 30,																Change
		2014								2013
		Amount				%				Amount				%				Amount				%
		(U.S. dollars in millions, except percentage)
Human Albumin			44.3				38.1				43.3				40.2				1.0				2.3
Immunoglobulin products:
IVIG			47.0				40.4				46.8				43.5				0.2				0.4
Other Immunoglobulin products			13.3				11.4				10.6				9.9				2.7				25.5
Placenta Polypeptide			9.7				8.3				5.2				4.8				4.5				86.5
Others			2.0				1.8				1.7				1.6				0.3				17.6
Totals			116.3				100.0				107.6				100.0				8.7				8.1

 

During the six months ended June 30, 2014 as compared to the six months ended June 30, 2013:

 

·

the average price for our approved human albumin products, which accounted for 38.1% of our total sales for the six months ended June 30, 2014, increased by approximately 2.2%, and excluding the foreign exchange translation effect, their average price in RMB term increased by approximately 0.5%; and

 

·

the average price for our approved IVIG products, which accounted for 40.4% of our total sales for the six months ended June 30, 2014, decreased by approximately 0.6%, and excluding the foreign exchange translation effect, their average price in RMB term decreased by approximately 2.1%.

 

The price increase of human albumin products was due to the impact of a higher retail price ceiling announced by China National Development and Reform Commission that became effective on February 1, 2013. This increased retail price ceiling provided us with more flexibility in pricing our human albumin products and allowed us to increase our ex-factory prices in certain regional markets. The price decrease of IVIG products, excluding the foreign exchange translation effect, was mainly attributable to the increased sales through distributors in tier one cities. To improve brand recognition in the six months ended June 30, 2014, we increased the market share of our IVIG products in tier one cities through distributors by lowering sales prices, resulting in a decline on the average sales prices of these products.

 

The sales volume of our human albumin products remained stable for the six months ended June 30, 2014 as compared to the same period in 2013. The increased sales volume in Shandong Taibang was offset by the decreased sales volume in Guizhou Taibang as a result of the planned production suspension at Guizhou Taibang from June 2013 to March 2014. The increase of the sales volume in Shandong Taibang was in line with the increase of the market demand for domestic human albumin as a result of the decreased importation in the six months ended June 30, 2014. The sales volume of our IVIG products remained stable for the six months ended June 30, 2014 as compared to the same period in 2013. The increased sales volume of IVIG in Shandong Taibang was offset by the decreased sales volume in Guizhou Taibang due to the reduced production volume as a result of the planned production suspension at Guizhou Taibang. The increase of the sales volume at Shandong Taibang was mainly due to the increased market demand as a result of the outbursts of HFMD and the increased sales through distributors in tier one cities during the six months ended June 30, 2014 as compared to the same period in 2013.

 

  

The sales increase of other immunoglobulin products during the six months ended June 30, 2014 as compared to the same period in 2013 was mainly attributable to the increase in sales volume of human rabies immunoglobulin products, partially offset by the decrease in sales volume of human tetanus immunoglobulin products. The increase in sales volume of human rabies immunoglobulin was primarily a result of increased production volume during this period. We increased the supply of rabies vaccinated plasma and expanded their production in Shandong Taibang starting in the second half of 2013. The improvements on production yield as a result of our research and development efforts also contributed to the increase of production volume. During the six months ended June 30, 2014, we increased our sales of human rabies immunoglobulin products by $4.4 million as compared to the same period in 2013. The decrease in sales volume of human tetanus immunoglobulin products was primarily a result of the planned production suspension at Guizhou Taibang from June 2013 to March 2014.

 

The sales increase of placenta polypeptide products was mainly in line with the volume increase for the six months ended June 30, 2014 as compared to the same period in 2013. The sales volume of placenta polypeptide products increased by 89% for the six months ended June 30, 2014 as compared to the same period in 2013. This increase was due to the expanded production of placenta polypeptide at Guizhou Taibang after its receipt of the GMP certification for the upgraded production facilities of placenta polypeptide in January 2014.

 

Cost of sales & gross profit

		For the six months ended June 30,								Change
		2014				2013				Amount				%
		(U.S. dollars in millions, except percentage)
Cost of sales			36.6				32.7				3.9				11.9	%
as a percentage of total sales			31.5	%			30.4	%							1.1	%
Gross Profit			79.7				74.9				4.8				6.4	%
Gross Margin			68.5	%			69.6	%							(1.1	)%

 

Our cost of sales was $36.6 million, or 31.5% of our sales for the six months ended June 30, 2014, as compared to $32.7 million, or 30.4% of our sales for the same period in 2013. Our gross profit was $79.7 million and $74.9 million for the six months ended June 30, 2014 and 2013, respectively, representing gross margins of 68.5% and 69.6%, respectively. Our cost of sales and gross margin are affected by the volume and pricing of our sold products, raw material costs, production mix and respective yields, inventory provisions, production cycles and routine maintenance costs.

 

The increase in cost of sales in the six month ended June 30, 2014 as compared to the same period in 2013 was largely in line with the increases in sales volume and cost of plasma. In an effort to increase plasma collection volume and expand our donor base, we increased the nutrition fees paid to donors consistent with the industry practice. We expected the nutrition fees to be paid to donors continue to increase as a result of improving living standards in China. Consequently, future improvements on margins will need to be derived from increases in product pricing and volume, product mix, yields and manufacturing efficiency. The increase in cost of sales as a percentage of sales for the six month ended June 30, 2014 as compared to the same period in 2013 was mainly due to the increase in cost of plasma partially offset by the change of our product mix to include products with higher margins.

 

Operating expenses

 

		For the six months ended June 30,								Change
		2014				2013				Amount				%
		(U.S. dollars in millions, except percentage)
Operating expenses			22.9				23.6				(0.7	)			(3.0	)%
as a percentage of total sales			19.6	%			21.9	%							(2.3	)%

 

Our total operating expenses decreased by $0.7 million, or 3.0%, to $22.9 million for the six months ended June 30, 2014, from $23.6 million for the same period in 2013. As a percentage of sales, total expenses decreased by 2.3% to 19.6% for the six months ended June 30, 2014, from 21.9% for the same period in 2013. The decrease of the total operating expenses was a combined effect of the decrease of the general and administrative expenses and the increase of the selling expenses and research and development expenses as discussed below.

 

  

Selling expenses

 

		For the six months ended June 30,								Change
		2014				2013				Amount				%
		(U.S. dollars in millions, except percentage)
Selling expenses			5.6				4.3				1.3				30.2	%
as a percentage of total sales			4.8	%			4.0	%							0.8	%

 

Our selling expenses increased by $1.3 million, or 30.2%, to $5.6 million for the six months ended June 30, 2014, from $4.3 million for the same period in 2013. As a percentage of sales, our selling expenses for the six months ended June 30, 2014 increased by 0.8% to 4.8%, from 4.0% for the same period in 2013. The increase was mainly due to the increased sales of placenta polypeptide for the six months ended June 30, 2014 as compared to the same period in 2013. Compared with other products, placenta polypeptide has a relatively higher per unit selling expenses.

 

General and administrative expenses

		For the six months ended June 30,								Change
		2014				2013				Amount				%
		(U.S. dollars in millions, except percentage)
General and administrative expenses			14.3				17.6				(3.3	)			(18.8	)%
as a percentage of total sales			12.3	%			16.3	%							(4.0	)%

 

Our general and administrative expenses decreased by $3.3 million, or 18.8%, to $14.3 million for the six months ended June 30, 2014, from $17.6 million for the same period in 2013. General and administrative expenses as a percentage of sales decreased by 4.0% to 12.3% for the six months ended June 30, 2014, from 16.3% for the same period in 2013. The decrease in general and administrative expenses was mainly due to a decrease in legal expenses. In the six months ended June 30, 2013, we incurred legal expenses in relation to the take-over defense against one of our direct competitors in China. We did not incur similar legal expenses for the six months ended June 30, 2014. In addition, we incurred amortization expenses in the six months ended June 30, 2013 with respect to the GMP certificates and certain other intangible assets which were part of our acquisition of Guizhou Taibang in 2008. Because such intangible assets had been fully amortized by the end of 2013, we did not incur corresponding expenses in the six months ended June 30, 2014.

 

Research and development expenses

		For the six months ended June 30,								Change
		2014				2013				Amount				%
		(U.S. dollars in millions, except percentage)
Research and development expenses			2.9				1.7				1.2				70.6	%
as a percentage of total sales			2.5	%			1.6	%							0.9	%

 

Our research and development expenses increased by $1.2 million, or 70.6%, to $2.9 million for the six months ended June 30, 2014, from $1.7 million for the same period in 2013. As a percentage of sales, our research and development expenses for the six months ended June 30, 2014 and 2013 were 2.5% and 1.6%, respectively. The increase in research and development expenses was mainly due to the expenditure paid for certain clinical trial programs and the engagement of external experts for certain pipeline products for the six months ended June 30, 2014.

 

Income tax

		For the six months ended June 30,								Change
		2014				2013				Amount				%
		(U.S. dollars in millions, except percentage)
Income tax			9.8				8.4				1.4				16.7	%
as a percentage of total sales			8.4	%			7.8	%							0.6	%

 

Our provision for income taxes increased by $1.4 million, or 16.7%, to $9.8 million for the six months ended June 30, 2014, from $8.4 million for the same period in 2013. Our effective income tax rates were 16.2% and 15.7% for the six months ended June 30, 2014 and 2013, respectively. The effective income tax rate remained consistent for the six months ended June 30, 2014 and 2013. Tax rate applicable to our major operating subsidiaries in the PRC for 2014 and 2013 is 15%.

 

  

Liquidity and Capital Resources

 

To date, we have financed our operations primarily through cash flows from operations, augmented by bank borrowings and equity contributions by our stockholders. As of June 30, 2014, we had $103.2 million in cash and cash equivalents, primarily consisting of cash on hand and demand deposits.

 

The following table provides the summary of our cash flows for the periods indicated:

		For the six months ended June 30,
		2014				2013
		(U.S. dollars in millions)
Net cash provided by operating activities			39.0				37.9
Net cash used in investing activities			(3.0	)			(12.4	)
Net cash used in financing activities			(76.2	)			(10.6	)
Effects of exchange rate change on cash			(0.7	)			2.8
Net (decrease) increase in cash and cash equivalents			(40.9	)			17.7
Cash and cash equivalents at beginning of the period			144.1				129.6
Cash and cash equivalents at end of the period			103.2				147.3

 

Operating Activities

 

Net cash provided by operating activities for the six months ended June 30, 2014 was $39.0 million, as compared to $37.9 million for the same period in 2013. The increase in net cash provided by operating activities was primarily due to the increase in net income for the six months ended June 30, 2014 as compared to the same period in 2013, partially offset by the increase of accounts receivable and the inventories during this period. Accounts receivable increased by $7.5 million in line with the sales increase during the six months ended June 30, 2014, as compared to $6.3 million during the same period in 2013. Inventories increased by $6.9 million during the six months ended June 30, 2014, as compared to $3.6 million during the same period in 2013. This increase was primarily due to an increase in raw materials as a result of the continued supply of plasma, our primary raw material, by plasma stations of Guizhou Taibang while its production of plasma products had been suspended from June 2013 to March 2014.

 

Investing Activities

 

Net cash used in investing activities for the six months ended June 30, 2014 was $3.0 million, as compared to $12.4 million for the same period in 2013. During the six months ended June 30, 2014 and 2013, we paid $11.5 million and $13.1 million, respectively, for the acquisition of property, plant and equipment, intangible assets and land use right for Shandong Taibang and Guizhou Taibang. On the other hand, during the six months ended June 30, 2014, we received a refund of deposit of $1.6 million from the local government due to the decrease in the size of a parcel of land to be granted to us in Guizhou. In addition, we had a time deposit of $6.6 million mature during the six months ended June 30, 2014, which resulted in a net cash inflow from investing activities.

 

Financing Activities

 

Net cash used in financing activities for the six months ended June 30, 2014 totaled $76.2 million, as compared to $10.6 million for the same period in 2013. The net cash used in financing activities for the six months ended June 30, 2014 was mainly consisted of a payment of $70.0 million for share repurchase, a deposit of $72.3 million as cash collateral for certain long-term bank loans, a repayment of $4.9 million on a short-term bank loan, and a dividend of $1.4 million paid by our subsidiaries to the noncontrolling interest shareholders, partially offset by proceeds of $70.0 million from certain long-term bank loans and proceeds of $1.6 million from the exercise of stock options. The net cash used in financing activities for the six months ended June 30, 2013 was mainly due to a repayment of $8.0 million of short-term bank loans and a dividend of $8.1 million paid by our subsidiaries to the noncontrolling interest shareholders, partially offset by the proceeds of $4.8 million from short-term bank loans and the proceeds of $2.7 million from the exercise of stock options.

 

Management believes that the Company has sufficient cash on hand and continuing positive cash inflow, from the sale of its products in the PRC market, for its operations.

 

  

Obligations under Material Contracts

 

The following table sets forth our material contractual obligations as of June 30, 2014:

 

		Payments Due by Period
Contractual Obligations		Total				Less than one year				One to three years				Three to five years				More than five years
		(U.S. dollars in millions)
Short-term bank loans			4.9				4.9				-				-				-
Long-term bank loans, including current portion			100.0				30.0				70.0				-				-
Interest on bank loans			3.7				2.8				0.9				-				-
Operating lease commitment			1.0				0.5				0.4				-				0.1
Capital commitment			5.2				4.7				0.5				-				-
Total			114.8				42.9				71.8				-				0.1

 

Seasonality of Our Sales

 

Our operating results and operating cash flows historically have not been subject to seasonal variations. This pattern may change, however, as a result of new market opportunities or new product introductions.

 

Inflation

 

Inflation does not materially affect our business or the results of our operations.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our investors.

 

Critical Accounting Policies

 

Critical accounting policies are those we believe are most important to portraying our financial conditions and results of operations and also require the greatest amount of subjective or complex judgments by management. Judgments and uncertainties regarding the application of these policies may result in materially different amounts being reported under various conditions or using different assumptions. There have been no material changes to the critical accounting policies previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Our operations are carried out in the PRC and we are subject to specific considerations and significant risks not typically associated with companies in North America and Western Europe. Accordingly, our business, financial condition and results of operations may be influenced by the political, economic and legal environment in the PRC, and by the general state of the PRC economy. Our results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.

 

Interest Rate Risk

 

We are exposed to interest rate risk primarily with respect to our bank loans. We have not used any derivative financial instruments to manage our interest rate risk exposure. We have not been exposed nor do we anticipate being exposed to material risks due to changes in interest rates. However, our future interest expenses may increase due to changes in market interest rates.

 

A hypothetical 1.0% increase in the annual interest rates for all of our credit facilities under which we had outstanding borrowings as of June 30, 2014 would result in decrease of net income before provision for income taxes by approximately $0.5 million for the six months ended June 30, 2014.

 

Management monitors the banks’ prime rates in conjunction with our cash requirements to determine the appropriate level of debt balances relative to other sources of funds. We have not entered into any hedging transactions in an effort to reduce our exposure to interest rate risk.

 

  

Foreign Exchange Risk

 

All of our consolidated revenues and consolidated costs and majority of expenses are denominated in RMB. All of our assets are denominated in RMB, except certain cash balances. However, certain of our loan facilities are denominated in U.S. dollars and our reporting currency is U.S. dollars. As a result, we are exposed to foreign exchange risk as our revenues and results of operations may be affected by fluctuations in the exchange rate between U.S. dollars and RMB. If RMB depreciates against the U.S. dollars, the value of our RMB revenues, earnings and assets as expressed in our U.S. dollar financial statements will decline. Assets and liabilities are translated at exchange rates at the balance sheet dates and revenue and expenses are translated at the average exchange rates and shareholders’ equity is translated at historical exchange rates. Any resulting translation adjustments are not included in determining net income but are included in determining other comprehensive income, a component of stockholders’ equity. We have not entered into any hedging transactions in an effort to reduce our exposure to foreign exchange risk.

 

The value of the RMB against the U.S. dollars and other currencies is affected by, among other things, changes in China’s political and economic conditions. Since July 2005, the RMB has not been pegged to the U.S. dollars. Although the People’s Bank of China regularly involved in the foreign exchange market to prevent significant short-term fluctuations in the exchange rate, the RMB may appreciate or depreciate significantly in value against the U.S. dollars in the medium to long term. Moreover, it is possible that in the future, PRC authorities may lift restrictions on fluctuations in RMB exchange rate and lessen involvement in the foreign exchange market.

 

Account Balances

 

We maintain balances at financial institutions which, from time to time, may exceed Federal Deposit Insurance Corporation insured limits for the banks located in the United States or may exceed Hong Kong Deposit Protection Board insured limits for the banks located in Hong Kong. Balances at financial institutions or state-owned banks within the PRC are not covered by insurance. Total cash at banks and deposits as of June 30, 2014 and December 31, 2013 amounted to $205.0 million and $180.9 million, respectively, $0.3 million and $0.7 million of which are covered by insurance, respectively. We have not experienced any losses in such accounts and we do not believe that we are exposed to any significant risks on our cash at banks and deposits.

 

Inflation

 

Inflationary factors such as increases in the cost of our sales and overhead costs may adversely affect our operating results. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, a high rate of inflation in the future may have an adverse effect on our ability to maintain current levels of gross margin and selling, general and administrative expenses as a percentage of net sales if the selling prices of our products do not increase with these increased costs.

 

Market for Human Albumin and IVIG

 

Our two major products, human albumin and IVIG, accounted for 38.1% and 40.4% of the total sales for the six months ended June 30, 2014, respectively. If the market demands for human albumin or IVIG cannot be sustained in the future or if there is substantial price decrease in either or both products, our operating results could be materially and adversely affected.

 

ITEM 4.

CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). Disclosure controls and procedures refer to controls and other procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

 

As required by Rule 13a-15(e), our management has carried out an evaluation, with the participation and under the supervision of our Chief Executive Officer, Mr. David (Xiaoying) Gao and our Chief Financial Officer, Mr. Ming Yang, of the effectiveness of the design and operation of our disclosure controls and procedures, as of June 30, 2014. Based on that evaluation, Mr. Gao and Mr. Yang concluded that our disclosure controls and procedures were effective as of June 30, 2014.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting during the three months ended June 30, 2014 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

  

PART II

OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

From time to time, we may become involved in various lawsuits and legal proceedings arising in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these, or other matters, may arise from time to time that may harm our business. Other than the legal proceedings set forth below, we are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.

 

Dispute among Guizhou Taibang Shareholders over Raising Additional Capital

 

In May 2007, a 91% majority of Guizhou Taibang’s shareholders approved a plan to raise additional capital from private strategic investors through the issuance of an additional 20,000,000 shares of Guizhou Taibang at RMB2.80 per share. The plan required all existing Guizhou Taibang shareholders to waive their rights of first refusal to subscribe for the additional shares. The remaining 9% minority shareholder of Guizhou Taibang’s shares, Guizhou Jie’an Company, or Jie’an, did not support the plan and did not waive its right of first refusal. In May 2007, the majority shareholders caused Guizhou Taibang to sign an Equity Purchase Agreement with certain investors, pursuant to which the investors agreed to invest an aggregate of $7,475,832 (or RMB50,960,000) in exchange for 18,200,000 shares, or 21.4%, of Guizhou Taibang’s equity interests. At the same time, Jie’an also subscribed for 1,800,000 shares, representing its pro rata share of the 20,000,000 shares being offered. The proceeds from all parties were received by Guizhou Taibang in accordance with the agreement.

 

In June 2007, Jie’an brought suit in the High Court of Guizhou province, China, against Guizhou Taibang and the three other original shareholders of Guizhou Taibang, alleging the illegality of the Equity Purchase Agreement. In its complaint, Jie’an claimed that it had a right to acquire the 18,200,000 shares offered to the strategic investors under the Equity Purchase Agreement. In September 2008, the Guizhou High Court ruled against Jie’an and sustained the Equity Purchase Agreement. In November 2008, Jie’an appealed the Guizhou High Court judgment to the People’s Supreme Court in Beijing. In May 2009, the People’s Supreme Court sustained the original ruling and denied the rights of first refusal of Jie’an over the 18,200,000 shares.

 

During the second quarter of 2010, Jie’an requested that Guizhou Taibang register its 1.8 million shares of additional capital injection with the local Administration for Industry and Commerce, or AIC, pursuant to the Equity Purchase Agreement, and such request was approved by the majority shareholders of Guizhou Taibang in a shareholders meeting held in the second quarter of 2010. However, the Board of Directors of the Company is withholding its required ratification of the shareholders’ approval of Jie’an’s request, pending the outcome of the ongoing litigation. In March 2012, the Company received a subpoena that Jie’an brought suit in the People’s Court of Huaxi District, Guizhou Province, against Guizhou Taibang, alleging Guizhou Taibang’s withholding of its request. Jie’an requested that Guizhou Taibang register its 1.8 million shares of capital injection, pay dividends associated with these shares, as well as the related interest and penalty from May 2007 to December 2011 amounting to $3,967,500 (or RMB25 million) in aggregate, and return the over-paid subscription of $228,528 (or RMB1,440,000), as well as the interest and penalty, amounting to $1,587,000 (or RMB10,000,000) in aggregate. The People’s Court of Huaxi District, Guizhou Province, has accepted Jie’an’s suit. In May 2012, Guizhou Taibang was informed by the court that the case was postponed upon the request from Jie’an. In July 2013, the People’s Court of Huaxi District issued an order declaring that the suit shall be set aside because the court has no jurisdiction over the suit. Jie’an did not appeal the case to the upper-level court.

 

In December 2013, Jie’an brought suit again in the People’s Court of Huaxi District, Guizhou Province, against Guizhou Taibang, alleging that Guizhou Taibang withheld Jie’an’s request to register 1.8 million shares under its name with the local AIC. The People’s Court of Huaxi District, Guizhou Province, accepted Jie’an’s suit and heard the case on February 26, 2014. In July 2014, the People’s Court of Huaxi District ruled against Jie’an, denying its request to register such shares. However, as part of its ruling, the People’s Court of Huaxi District ordered the Company to pay dividends of $2,240,542 (or RMB 13.8 million) associated with these shares and the related interest expenses to Jie’an. Both the Company and Jie’an appealed the case to the upper-level court in July 2014. As this case should be closely tied to the outcome of the strategic investors’ dispute stated below, the Company does not expect Jie’an to prevail.

 

In November 2013, Guizhou Taibang held a shareholders meeting and the shareholders passed resolutions, or the Resolutions, that, inter alia, (i) determined that it was no longer necessary for Guizhou Taibang to obtain additional capital from investors; (ii) rejected Jie'an's request that Jie'an subscribe for additional shares of Guizhou Taibang alone and one or more other shareholders reduce their shareholding in Guizhou Taibang; and (iii) approved the issuance of a total of 20,000,000 new shares to all existing shareholders on a pro rata basis. In December 2013, in addition to its lawsuit against Guizhou Taibang for Guizhou Taibang's failure to register its purchase of 1,800,000 shares in 2007 with the local AIC before the People's Court of Huaxi District, Guiyang, Jie'an filed another lawsuit against Guizhou Taibang with the People’s Court of Huaxi District and requested that the court declare the Resolutions void. The case was heard on March 6, 2014. In July 2014, the People’s Court of Huaxi District ruled against Jie’an, denying its request to declare the Resolutions void. Jie’an appealed the case to the upper-level court on July 28, 2014. The Company does not expect Jie’an to prevail.

 

  

If the Company decides to ratify the approval or the case is ruled in Jie’an’s favor, Dalin’s ownership in Guizhou Taibang will be diluted from 54% to 52.54% and Jie’an may be entitled to receive its pro rata share of Guizhou Taibang’s profits since the date on which Jie’an’s capital contribution became effective. As this case is closely tied to the outcome of the strategic investors’ dispute stated below, the Company does not expect Jie’an to prevail. As of June 30, 2014, the Company had recorded, in its balance sheet, payables to Jie’an in the amounts of RMB5,040,000 (approximately $0.8 million) for the additional funds received in relation to the 1.8 million shares of capital infusion, RMB1,440,000 (approximately $0.2 million) for the over-paid subscription and RMB3,135,095 (approximately $0.5 million) for the accrued interest.

 

As a result of this dispute, the strategic investors’ equity ownership in Guizhou Taibang and the related increase in registered capital of Guizhou Taibang have not been registered with the local AIC. In January 2010, the strategic investors brought suit in the High Court of Guizhou Province against Guizhou Taibang alleging Guizhou Taibang’s failure to register their equity interest in Guizhou Taibang with the local AIC and requesting the distribution of their share of Guizhou Taibang’s dividends declared since 2007. Dalin was also joined as a co-defendant as it is the majority shareholder and exercises control over Guizhou Taibang’s day-to-day operations.

 

In October, 2010, the High Court of Guizhou ruled in favor of the Company and denied the strategic investors’ right as shareholders of Guizhou Taibang, as well as their entitlement to the dividends. In light of this ruling, the Company returned the proceeds of $1,699,040 (or RMB11,200,000) to one of the strategic investors in November 2010. In October 2010, the other strategic investors appealed to the PRC Supreme Court in Beijing on the ruling of the High Court of Guizhou. The PRC Supreme Court overruled the decision of the High Court of Guizhou and remanded the case to the High Court of Guizhou for retrial. In January 2012, the strategic investors re-filed their case to the High Court of Guizhou requesting, in addition to the share distribution, the distribution of dividends and interest in the amount of RMB18,349,345 (approximately $3.0 million) and RMB2,847,000 (approximately $0.5 million), respectively. In December 2012, the High Court of Guizhou affirmed the judgment against the strategic investors. In January 2013, the strategic investors appealed to the PRC Supreme Court on the ruling again and the appeal was accepted.

 

In September 2013, the PRC Supreme Court made the final judgment against the strategic investors and denied the strategic investors’ right as shareholders of Guizhou Taibang and their claim for the related dividend distribution. In November 2013, the strategic investors requested the PRC Supreme Court to reconsider the judgment and such request was rejected by the PRC Supreme Court on January 17, 2014. As of June 30, 2014, Guizhou Taibang had made provision for the strategic investors’ initial fund along with RMB18,387,378 (approximately $3.0 million) in accrued interest, and RMB509,600 (approximately $80,000) for the 1% penalty imposed by the agreement for any breach in the event that Guizhou Taibang is required to return their original investment amount to the strategic investors.

 

In April 2013, the Company countersued the strategic investors in the Intermediate Court of Guiyang City alleging their breach of the Security Law in the PRC and requested a consideration of $6,064,800 (or RMB38 million) for the related expenses and losses, and Guizhou Intermediate Court accepted the case. In November 2013, the Company withdrew this suit as part of its claims therein had been affirmed in the rulings of the PRC Supreme Court.

 

ITEM 1A.

RISK FACTORS.

 

As of the date of this filing, there have been no material changes from the risk factors disclosed in the Company’s Annual Report on Form 10-K filed on March 12, 2014 and Current Report on Form 8-K filed on June 6, 2014. We operate in a changing environment that involves numerous known and unknown risks and uncertainties that could materially affect our operations. The risks, uncertainties and other factors set forth in the above-referenced Annual Report on Form 10-K and Current Report on Form 8-K may cause our actual results, performances and achievements to be materially different from those expressed or implied by our forward-looking statements. If any of these risks or events occurs, our business, financial condition or results of operations may be adversely affected.

 

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

We have not sold any equity securities during the three months ended June 30, 2014 that were not previously disclosed in a quarterly report on Form 10-Q or a current report on Form 8-K that was filed during this period. No repurchases of our common stock were made during the three months ended June 30, 2014.

 

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES.

 

None.

 

ITEM 4.

MINE SAFETY DISCLOSURES.

 

Not applicable.

 

ITEM 5.

OTHER INFORMATION.

 

We have no information to disclose that was required to be in a report on Form 8-K during the three months ended June 30, 2014, but was not reported. There have been no material changes to the procedures by which security holders may recommend nominees to our board of directors.

 

  

ITEM 6.

EXHIBITS.

 

The list of exhibits in the Exhibit Index to this report is incorporated herein by reference.

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: August 5, 2014	CHINA BIOLOGIC PRODUCTS, INC.
	By:	/s/ David (Xiaoying) Gao
		David (Xiaoying) Gao, Chief Executive Officer
		(Principal Executive Officer)

 

	By:	/s/ Ming Yang
		Ming Yang, Chief Financial Officer
		(Principal Financial Officer and Principal Accounting Officer)

 

 

EXHIBIT INDEX

 

Exhibit No.		Description
3.1		Second Amended and Restated Certificate of Incorporation of China Biologic Products, Inc.
3.2		Third Amended and Restated Bylaws of China Biologic Products, Inc.
31.1		Certifications of Principal Executive Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certifications of Principal Financial Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certifications of Principal Executive Officer furnished pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2		Certifications of Principal Financial Officer furnished pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101		Interactive data files pursuant to Rule 405 of Regulation S-T (furnished herewith)